Claudio Belluco

Claudio Belluco

Auto-generated profile, based on publicly available information

Claudio Belluco

National Cancer Institute

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2006 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
EPEmanuel F. Petricoin
Emanuel F. Petricoin
CBClaudio Belluco
Claudio Belluco
RARobyn P. Araujo
Robyn P. Araujo
LLLance A. Liotta
Lance A. Liotta

1 March 2000 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CBClaudio Belluco
Claudio Belluco
DNDonato Nitti
Donato Nitti
MFMarylin Frantz
Marylin Frantz
PTPaola Toppan
Paola Toppan
Daniela BassoDaniela Basso
Daniela Basso
JJJ. Milburn Jessup
J. Milburn Jessup

1 January 2003 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DNDonato Nitti
Donato Nitti
AMAlberto Marchet
Alberto Marchet
MOMatteo Olivieri
Matteo Olivieri
AAAlessandro Ambrosi
Alessandro Ambrosi
RMRoberto Mencarelli
Roberto Mencarelli
MLMario Lise
Mario Lise

21 February 2005 in Cytokine
Verified
Journal Article
Closed access
CZCarlo-F Zambon
Carlo-F Zambon
Daniela BassoDaniela Basso
Daniela Basso
FNFilippo Navaglia
Filippo Navaglia
CBClaudio Belluco
Claudio Belluco
AFAlessandra Falda
Alessandra Falda
MPMario Plebani
Mario Plebani

20 May 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EPEmanuel F. Petricoin
Emanuel F. Petricoin
VBVerena E. Bichsel
Verena E. Bichsel
VCValerie S. Calvert
Valerie S. Calvert
VEVirginia Espina
Virginia Espina
MWMary Winters
Mary Winters
LLLance A. Liotta
Lance A. Liotta
Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network of intracellular and extracellular signaling cascades. These protein signaling circuits are the ultimate targets of molecular therapy. Each patient's tumor may be driven by a distinct series of molecular pathogenic defects. Thus, for any single molecular targeted therapy, only a subset of cancer patients may respond. Individualization of therapy, which tailors a therapeutic regimen to a tumor molecular portrait, may be the solution to this dilemma. Until recently, the field lacked the technology for molecular profiling at the genomic and proteomic level. Emerging proteomic technology, used concomitantly with genomic analysis, promises to meet this need and bring to reality the clinical adoption of molecular stratification. The activation state of kinase-driven signal networks contains important information relative to cancer pathogenesis and therapeutic target selection. Proteomic technology offers a means to quantify the state of kinase pathways, and provides post-translational phosphorylation data not obtainable by gene arrays. Case studies using clinical research specimens are provided to show the feasibility of generating the critical information needed to individualize therapy. Such technology can reveal potential new pathway interconnections, including differences between primary and metastatic lesions. We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material.

8 February 2008 in Journal of Proteome Research
Verified
Journal Article
Closed access
JWJulia D. Wulfkuhle
Julia D. Wulfkuhle
RSRuna Speer
Runa Speer
MPMariaelena Pierobon
Mariaelena Pierobon
JLJulie Laird
Julie Laird
VEVirginia Espina
Virginia Espina
EPEmanuel F. Petricoin
Emanuel F. Petricoin